Syngene Expands with New GMP Bioconjugation Facility

December 29, 2025

Syngene International Limited

Syngene International is establishing a new GMP bioconjugation suite at its Bengaluru biologics facility (Unit 3). The advanced OEB-5-rated unit will support antibody-drug conjugate (ADC) manufacturing from research to commercial scale. It will integrate monoclonal antibody production and GMP conjugation under one roof, improving efficiency for clinical and commercial programs. This expansion strengthens Syngene’s CRDMO capabilities and reinforces India’s position in advanced biologics development and high-potency drug manufacturing.

Location: Bengaluru Karnataka

Estimated Value (Rs. Cr): NA

Sector: Drugs/Pharma

Project Stage: Conceptual/Planning

Contact Details: You need to be a paid subscriber to get these details. Contacts are available in the ProjectX India 01-11-2025 PDF Edition.

. Do you want to buy this issue or our latest issue? If yes! click here

*Image used in this post if any, is for illustration only

India Projects News | Drugs/Pharma sector Project News

ProjectX India’s fortnightly PDF edition delivers comprehensive coverage of new projects in India across sectors such as construction, infrastructure, power, energy, industrial, and consultancy. Stay updated with upcoming and ongoing projects, contract awards, tenders, and procurement opportunities that can drive your business growth. Each edition gives you actionable project leads, verified contacts, and the latest project insights, helping you stay ahead of competitors. Delivered directly to your inbox every fortnight, ProjectX India is your trusted source for project news and opportunities in India.